ViiV Healthcare’s Cabenuva and Dovato strategy looks like an ecosystem play as ultra long-acting candidates advance
ViiV Healthcare heads to CROI 2026 with ultra long-acting HIV data for VH4524184, VH4011499 and more. See what it changes next.
Why Harmony Biosciences’ pitolisant approval changes the risk calculus in pediatric narcolepsy
FDA approval expands pitolisant into pediatric cataplexy. Explore what this changes for narcolepsy care, safety, and long-term strategy.
How the Prostate Cancer Foundation’s $6.3m bet on young investigators could shape the next decade of prostate cancer innovation
Discover why the Prostate Cancer Foundation’s $6.3 million investment in young researchers could shape the future of prostate cancer diagnostics and treatment.
Why Watchmaker Genomics is repurposing CRISPR-Cas9 to reshape NGS library normalization at scale
Watchmaker Genomics is repurposing CRISPR-Cas9 to streamline NGS normalization. Find out why this matters for sequencing at scale.
Scribe Therapeutics deepens in vivo CRISPR validation with second Eli Lilly collaboration milestone
Scribe Therapeutics hits a second in vivo CRISPR milestone with Eli Lilly. Explore what this changes for gene editing platforms and future therapies.
Rallybio validates durable complement suppression with RLYB116 in Phase 1 study
Rallybio reports Phase 1 data for RLYB116 showing sustained complement inhibition. Find out what this changes for C5 therapies and what comes next.
NIM-1324 enters Phase 2 as NImmune Biopharma tests immunometabolism as the next frontier in inflammatory bowel disease
Discover how NImmune Biopharma’s NIM-1324 Phase 2 program could reshape inflammatory bowel disease treatment beyond biologics and JAK inhibitors.
Nimbus Therapeutics tests a dual inflammation and repair thesis with SIK2 inhibitors
Nimbus Therapeutics unveils SIK2 inhibitor data at ECCO 2026. Explore what this means for oral IBD therapies and mucosal healing strategies.
Why Pfizer’s BRAFTOVI results could reshape first-line treatment for BRAF-mutant mCRC
Pfizer reports positive BREAKWATER data for BRAFTOVI in BRAF-mutant mCRC. Find out what this could change for frontline colorectal cancer care.
Bristol Myers Squibb pushes CELMoD frontier as FDA accepts iberdomide NDA in relapsed multiple myeloma
FDA accepts Bristol Myers Squibb’s iberdomide NDA for relapsed multiple myeloma. Find out what this CELMoD filing could change next.